For a grade 3 phenotype, regardless of receptor status, these again were overrepresented occurring in 28/37 (75.7%) individuals with a PALB2 PGVs as compared with 562/1381 (40.7%) of all invasive ductal carcinomas known to our service and testing negative for BRCA1, BRCA2, and PALB2 PGVs (OR = 4.53, 95% CI = 2.11-9.65, P < 0.0001). The gene discussed is PALB2; the disease is invasive ductal breast carcinoma.